Embecta to shutter newly cleared insulin patch pump program …
4 days ago · For the 2024 fiscal year, Embecta reported revenues of $1.123 billion, for a gain of 0.2%, including fourth-quarter sales of $286.1 million. Annual net income reached $78.3 million, compared to ...
Embecta discontinues patch pump program, plans restructuring
4 days ago · A look at Embecta’s fourth-quarter results. Embecta reported profits of $14.6 million. That equals 25¢ per share on sales of $286.1 million for the three months ended Sept. 30, 2024. Embecta more than doubled its bottom line year over year on a sales increase of 1.5%. Adjusted to exclude one-time items, earnings per share came in at 45¢.
Embecta discontinues insulin patch pump development
4 days ago · MedTech industry news. Dive Insight: Embecta received FDA clearance for its insulin patch pump in September. The device is indicated for people with Type 1 or Type 2 diabetes and includes a 300-unit insulin reservoir to support people with higher daily insulin needs.. However, the version Embecta received clearance for was an open-loop patch pump, where users manually control insulin delivery ...
Embecta to discontinue insulin patch pump program, initiates ...
4 days ago · Devdatt (Dev) Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio and strategy, we have decided to discontinue our ...
Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year ...
4 days ago · PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. "We are pleased to report a strong fourth quarter and end
Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump …
4 days ago · Guidance: Embecta says that for the fiscal year 2025, excluding the Patch Pump program, revenues are expected to be $1.093 billion—$1.11 billion compared to a consensus of $1.12 billion, with an ...
Embecta Shares Surge on Solid Guidance, Restructuring Plan
4 days ago · On an adjusted basis, Embecta booked a full-year profit of $2.45 per share, 6 cents better than the analyst consensus and above its prior guidance of $2.30 to $2.35 per share.
Embecta Pumps the Brakes on Insulin Patch Pump Program
4 days ago · Embecta, which was spun out of Becton Dickinson in April of 2022, is instituting a restructuring plan that includes exiting the insulin patch pump program. The measure comes as the Readers’ Choice for 2022 Company of the Year , reported beating expectations in 4Q24 on adjusted revenue, margins, and earnings per share while setting FY2025 ...
Diabetes device firm Embecta considers sale: Financial Times
Jul 22, 2024 · Embecta has hired advisers as it considers a potential sale, the Financial Times reported late Friday. The Parsippany, N.J.-based company makes insulin syringes and pen needles for managing diabetes and is developing an insulin patch-pump for people with Type 2 …
News Release Details - embecta Corp.
PARSIPPANY, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced it has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system.